The blockbuster weight loss drug sold as Ozempic and Wegovy [has, on 21 March, gone] generic in countries that are home to 40 percent of the world’s population, significantly lowering the price of a costly medicine that had been largely unaffordable to nearly all but the wealthiest people. On Saturday, Novo Nordisk, the company that until now has had a monopoly on selling the drug, will lose patent protection in several of the world’s most populous countries. The first generic versions are expected to arrive in India as soon as this weekend. In the coming months, the generics are also expected to become available in China, Canada, Brazil, Turkey and South Africa.
Individual differences matter.
Some people are eating like a truck and can barely be called active, yet remain slim.
Some others put a much greater effort into keeping themselves in shape, stick to a diet, exercise a lot, and still don’t have it.
There are plenty of genuine issues that can make losing weight problematic. But taking random drugs without prescription like there’s no tomorrow is not going to help.